Post-Hoc Analyses from Pivotal Phase 3 REFLECT Trial of LENVIMA® (lenvatinib) in Unresectable Hepatocellular Carcinoma to be Presented at 2019 Gastrointestinal Cancers Symposium

By In The News
January 14, 2019 in The Headlines

Recommended Posts

In The News

Posted January 14, 2019

- Share

Posted January 14, 2019

WOODCLIFF LAKE, N.J., Jan. 14, 2019 /PRNewswire/ -- Eisai Inc. announced today the presentation of four abstracts at the 2019 Gastrointestinal Cancers Symposium (#GI19), taking place in San Francisco from January 17-19, 2019. The presentations feature the latest data from post-hoc...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  217767
2. Jaydee
  15755
3. Kip Powick
  12028
4. deicer
  11468
5. dagger
  9586
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  267.9k
- Total Posts
  
  553.5k

Sign In

Post-Hoc Analyses from Pivotal Phase 3 REFLECT Trial of LENVIMA® (lenvatinib) in Unresectable Hepatocellular Carcinoma to be Presented at 2019 Gastrointestinal Cancers Symposium

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support